Jussi Lehto

5PUBLICATIONS
27CO-AUTHORS
Predictive and prognostic markersInnate immunityRegenerative medicine (incl. stem cells)Medical infection agents (incl. prions)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Sep 30, 2026
Impact of Oral Cladribine on TSPO-PET-Measurable Immune Cell Activation in Multiple Sclerosis.

|May 16, 2025
Plasma CHI3L1 associates with brain volume loss and glial activation in multiple sclerosis.

Venla Ahola, Maija Saraste, Marjo Nylund

|Apr 29, 2025
Broad rim lesions are a new pathological and imaging biomarker for rapid disease progression in multiple sclerosis.

Luisa Klotz, Joost Smolders, Jussi Lehto

|Dec 05, 2024
P2X 7-receptor binding in new-onset and secondary progressive MS - a [11C]SMW139 PET study.

Jussi Lehto, Richard Aarnio, Jouni Tuisku

|May 08, 2023
Longitudinal stability of progression-related microglial activity during teriflunomide treatment in patients with multiple sclerosis.

Jussi Lehto, Marjo Nylund, Markus Matilainen

Pageof 1

Frequent Collaborators

3 joint publications

Markus Matilainen

3 joint publications

Laura Airas

2 joint publications

Sini Laaksonen

2 joint publications

Anna Vuorimaa